Veradermics, Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Reid Waldman
- Full Time Employees
- 21
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 470 James Street New Haven CT United States of America 06513
- IPO Date
- Feb 4, 2026
- CIK
- 0001827635
- Website
- veradermics.com
- Similar Companies
- Business
- Veradermics, Incorporated operates as a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for prevalent aesthetic and dermatological conditions, with an initial emphasis on pattern hair loss (PHL) and related dermatologic needs. The company pursues a comprehensive portfolio strategy centered on VDPHL01 and other dermatology- and aesthetics-focused programs, supported by an IP-backed platform designed to differentiate its therapies through improved safety, efficacy, and patient experience. Veradermics combines a clinical development pathway with a robust commercialization plan aimed at educating physicians and patients and establishing a leadership position in large, underserved patient populations. Founding and governance - Founded: 2010s (as a venture-backed, dermatology-focused enterprise pursuing late-stage development) - Headquarters: [United States, Connecticut area] (Veradermics maintains its executive and development activities in New Haven, with broader U.S. operations) Core products and services - VDPHL01: lead therapeutic candidate for male and female pattern hair loss (PHL), targeting restoration of hair growth through a novel mechanism of action; Phase 2/3 clinical development with pivotal trials intended to support potential regulatory approval - Additional dermatology/esthetic pipeline: late-stage and pre-clinical programs addressing common dermatologic conditions with high unmet need; potential oral and topical formulations; supportive diagnostic, biomarker, and companion diagnostic considerations to optimize patient selection and outcomes - Partnerships and collaborations: strategic relationships with contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and potential academic or pharmaceutical collaborators to accelerate development, manufacturing scale-up, and global access - Commercialization services: physician and patient education programs, patient access and reimbursement strategies, and field-based medical affairs activities designed to support product launches and lifecycle management - Intellectual property: a portfolio focused on protecting core innovations around PHL therapies and future dermatology/esthetics assets to sustain competitive differentiation Latest major company changes - Financing and clinical advancement: completes a significant Series B financing round to accelerate pivotal Phase 2/3 trials for VDPHL01 and to fund expansion of the dermatology/esthetics pipeline - Clinical progress: enrollment completion or ongoing advancement of pivotal Phase 2/3 trials for VDPHL01 in hair loss, with plans for potential expansion into additional indications in dermatology and aesthetic conditions - Corporate development: recent partnerships or strategic alliances to bolster development capability, manufacturing readiness, and regulatory strategy; potential corporate restructuring or strategic shifts to support accelerated commercial readiness in major markets - Market and corporate positioning: ongoing efforts to establish Veradermics as a leading aesthetics- and dermatology-focused biopharmaceutical company in the United States and select international markets, supported by targeted commercialization planning and payer strategies Industry context and markets - Industry: biotechnology/pharmaceuticals with a focus on dermatology, aesthetics, and hair restoration - Segments: clinical-stage drug development, dermatology therapeutics, aesthetics solutions, and related medical education and commercialization services - Target markets: large, underserved populations affected by pattern hair loss and other common dermatologic conditions; initial U.S. market emphasis with potential expansion into international markets - Subsidiaries/affiliations: operates as an independent company with a pipeline strategy that may involve strategic partnerships, potential licensing, or acquisition activity to complement internal development Additional notes - The company emphasizes a patient-centric approach to dermatology and aesthetics, aiming to deliver best-in-class therapies that address real-world needs where existing treatments fall short - Ongoing regulatory strategy, clinical readouts, and future product launches are central to Veradermics’ long-term growth and market penetration in the dermatology space
Veradermics: VDPHL01 Looks Promising Enough On Paper
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302' in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
Veradermics (NYSE:MANE) Shares Gap Up After Analyst Upgrade
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Veradermics' Oral VDPHL01 Delivers Positive Study ‘207' Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306' Readout
Veradermics to Hold Conference Call to Discuss Study ‘207' Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Biotech ETF Index Surges 10% After Rebalance
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
Veradermics, Incorporated (MANE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Veradermics to Present at Upcoming June Investor Conferences
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 '302' Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302' Study of VDPHL01 at the 2026 World Congress for Hair Research
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis
Veradermics Announces Launch of Public Offering
Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript